Oxyphenbutazone
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
|
|
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| ECHA InfoCard | 100.004.489 |
| Chemical and physical data | |
| Formula | C19H20N2O3 |
| Molar mass | 324.379 g/mol |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
|
|
|
|
| |
|
Oxyphenbutazone is a nonsteroidal anti-inflammatory drug (NSAID).[1] It is a metabolite of phenylbutazone.[2]
It was withdrawn from markets worldwide in mid-1980s due to bone marrow suppression and Stevens–Johnson syndrome.[3][4]
References[edit]
- ^ Singh, N.; Jabeen, T.; Somvanshi, R. K.; Sharma, S.; Dey, S.; Singh, T. P. (2004). "Phospholipase A2as a Target Protein for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Crystal Structure of the Complex Formed between Phospholipase A2and Oxyphenbutazone at 1.6 Å Resolution†". Biochemistry. 43 (46): 14577–14583. doi:10.1021/bi0483561. PMID 15544328.
- ^ Matthews, N. S.; Peck, K. E.; Taylor, T. S.; Mealey, K. L. (2001). "Pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in miniature donkeys". American journal of veterinary research. 62 (5): 673–675. PMID 11341383.
- ^ Fung, M.; Thornton, A.; Mybeck, K.; Wu, J. H.-h.; Hornbuckle, K.; Muniz, E. (1 January 2001). "Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999". Therapeutic Innovation & Regulatory Science. 35 (1): 293–317. doi:10.1177/009286150103500134.
- ^ Biron, P (15 May 1986). "Withdrawal of oxyphenbutazone: what about phenylbutazone?". Canadian Medical Association Journal. 134 (10): 1119–20. PMC 1491052
. PMID 3697857.
| This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it. |